TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31352906
Drug: Plasma retinol
Normalized name: retinol
DrugBank: Vitamin A (DB00162)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Plasma retinol levels (per 10 μg/dl increases)
Study: 31352906
Drug: Quartile 2-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quartile 2-4 retinol levels (≥ 52.3 μg/dl) compared to quartile 1 (< 52.3 μg/dl)
Study: 31352906
Drug: Plasma retinol
Normalized name: retinol
DrugBank: Vitamin A (DB00162)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Plasma retinol levels (per 10 μg/dl increases) in participants with retinol < 68.2 μg/dl
Study: 31352906
Drug: Plasma retinol
Normalized name: retinol
DrugBank: Vitamin A (DB00162)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Plasma retinol levels (per 10 μg/dl increases) in participants with retinol ≥ 68.2 μg/dl
Study: 29474547
Drug: Substance use
Normalized name: reSET Substance Use Disorder Therapy Software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Substance use treatment and trauma symptom management
Study: 26669430
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg of Ca (2·4 g Aquamin)
Study: 26669430
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg of Ca with 3 g of scFOS
Study: 22621166
Drug: G79 (primer
Approvals — FDA: no, EMA: no, PMDA: no
Description: G79 (primer application + heat treatment at 79°C) without aging
Study: 22621166
Drug: G100 (primer
Approvals — FDA: no, EMA: no, PMDA: no
Description: G100 (primer application + heat treatment at 100°C)
Study: 22621166
Drug: G45 (primer
Approvals — FDA: no, EMA: no, PMDA: no
Description: G45 (primer application + heat treatment at 45°C)
Study: 17388962
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg/day (group B)
Study: 11605079
Drug: d-amphetamine sulfate
Normalized name: amphetamine / dextroamphetamine
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-amphetamine sulfate (10 mg and 20 mg)
Study: 11605079
Drug: bupropion hydrochloride
Normalized name: Bupropion Hydrochloride
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: bupropion hydrochloride (150 mg and 300 mg)
Study: 4553818
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (AMCA, Cyclokapron), 1 g three times a day for five days
Study: 31005246
Drug: Standard analgesic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard analgesic treatment (arm A)
Study: 17011409
Drug: Faropenem medoxomil
Normalized name: Faropenem medoxomil
DrugBank: Faropenem medoxomil (DB05659)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faropenem medoxomil 300 mg twice daily for 7 days
Study: 17011409
Drug: Faropenem medoxomil
Normalized name: Faropenem medoxomil
DrugBank: Faropenem medoxomil (DB05659)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faropenem medoxomil 300 mg twice daily for 10 days
Study: 17011409
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil 250 mg twice daily for 10 days
Study: 11402108
Drug: IV immunoglobulin
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV immunoglobulin (IVIg) 0.4 g/kg daily for 5 days followed by three single infusions monthly for 3 months
Study: 3026294
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (Hydrochlorothiazide plus Enalapril)
Study: 24100256
Drug: Remifentanil target-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil target-controlled infusion
Study: 24100256
Drug: Dexmedetomidine single-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine single-dose administration (0.5 μg/kg given 10 minutes before the end of surgery)
Study: 24100256
Drug: Dexmedetomidine single-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine single-dose administration
Study: 25272534
Drug: 2% Diltiazem
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% Diltiazem gel applied twice daily for two weeks
Study: 14623690
Drug: Long-pulse 532-nm
Normalized name: LONG PEPPER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-pulse 532-nm Nd:YAG laser treatment
Study: 10638174
Drug: 0.1% isotretinoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% isotretinoin gel
Study: 10621853
Drug: 0.1% isotretinoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% isotretinoin gel after placebo
Study: 8961487
Drug: Sequential alternating
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential alternating chemotherapy (Adriamycin/cisplatin and bleomycin/vinblastine; 8.5 +/- 5 cycles)
Study: 8961487
Drug: Standard PEB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard PEB chemotherapy (cisplatinum/etoposide/bleomycin; 5.7 +/- 2.1 cycles)
Study: 8961487
Drug: Retroperitoneal lymph
Normalized name: Bos taurus lymph preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retroperitoneal lymph node dissection (RPLND) after chemotherapy
Study: 1809531
Drug: 4 basic
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 basic chemicals (imipramine, norephedrine, nicotine, 8-aminoquinoline) applied via a 24-hour patch
Study: 7073415
Drug: Colestipol hydrochloride
Normalized name: Colestipol Hydrochloride
DrugBank: Colestipol (DB00375)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colestipol hydrochloride (15, 20, and 30 g/day)
Study: 7073415
Drug: Clofibrate (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clofibrate (2.0 g/day)
Study: 27351320
Drug: Silodosin 8
Normalized name: silodosin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silodosin 8 mg daily
Study: 27351320
Drug: Lactose tablets
Normalized name: lactose Oral Tablet
DrugBank: Lactose (DB04465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose tablets (Control)
Study: 22107266
Drug: Preseasonal rush
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preseasonal rush immunotherapy using depigmented polymerized allergenic extract of mixed grass pollen
Study: 11802108
Drug: Terbinafine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine (250 mg)
Study: 10197230
Drug: Inhaled lignocaine
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled lignocaine 40 mg
Study: 10197230
Drug: Inhaled lignocaine
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled lignocaine 160 mg
Study: 3291558
Drug: Metoprolol (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (mean dose 197 mg/day)
Study: 3291558
Drug: Atenolol (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (mean dose 86 mg/day)
Study: 3291558
Drug: Propranolol (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (mean dose 305 mg/day)
Study: 30595565
Drug: Ergocalciferol (50,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ergocalciferol (50,000 IU weekly) with calcitriol (0.25 mg/d) for 3 months
Study: 27488472
Drug: belimumab 10
Normalized name: Belimumab
DrugBank: Belimumab (DB08879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: belimumab 10 mg/kg + standard of care (SoC)
Study: 27488472
Drug: belimumab 10
Normalized name: Belimumab
DrugBank: Belimumab (DB08879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: belimumab 10 mg/kg + steroids only
Study: 27488472
Drug: placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo + steroids only
Study: 27488472
Drug: belimumab 10
Normalized name: Belimumab
DrugBank: Belimumab (DB08879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: belimumab 10 mg/kg + steroids + AM
Study: 27488472
Drug: placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo + steroids + AM
Study: 17932136
Drug: ATP infusion
Normalized name: ATP
DrugBank: ATP (DB00171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATP infusion (80 mug (kg body mass)(‐1) min(‐1))
Study: 17932136
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no ATP infusion)
Study: 9475565
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone 10 mg once a day
Study: 8523629
Drug: Growth hormone,
Normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone, glutamine, and a modified high-carbohydrate, high-fiber diet
Study: 30687994
Drug: diacerein 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: diacerein 100 mg/day
Study: 27102407
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of workplace environmental dietary modification and educational intervention
Study: 25715572
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of iontophoresis and magnetic field (20 procedures)
Study: 21531481
Drug: HiDHA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: HiDHA supplementation (1000 mg of tuna oil; comprising 252 mg DHA, 60 mg EPA and 10 mg vitamin E)
Study: 21531481
Drug: Placebo (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1000 mg soybean oil)
Study: 10030765
Drug: Ropinirole plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropinirole plus L-dopa
Study: 7573879
Drug: Caudal block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal block using 0.125% bupivacaine with adrenaline + rectally administered diclofenac 1 mg.kg‐1
Study: 2344682
Drug: Nisoldipine 10
Normalized name: nisoldipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisoldipine 10 mg orally
Study: 2040325
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) 75 mg daily
Study: 24709264
Drug: Valacyclovir 500
Normalized name: valacyclovir 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valacyclovir 500 mg orally twice daily for 5 days (RESI-VAL)
Study: 24709264
Drug: Oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo (RESI-PLA)
Study: 24709264
Drug: Vehicle and
Normalized name: Vehicle and emulsifier patch test product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle and oral placebo (VEH-PLA)
Study: 22079954
Drug: Daily enteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily enteral zinc, selenium, glutamine, and intravenous metoclopramide (n = 149)
Study: 22079954
Drug: Daily enteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily enteral whey protein (n = 144)
Study: 15178151
Drug: Alpha‐lactalbumin supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha‐lactalbumin supplement combined with carbohydrates (AS)
Study: 11771585
Drug: Ni‐Ti Pow‐R
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ni‐Ti Pow‐R 0.04 ISO taper rotary files
Study: 11771585
Drug: Ni‐Ti ProFile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ni‐Ti ProFile 0.04 ISO taper rotary files
Study: 10099033
Drug: Delapril 30
Normalized name: Delapril
DrugBank: Delapril (DB13312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delapril 30 mg + Indapamide 1.25 mg once daily for 24 weeks
Study: 2952046
Drug: Foscarnet 0.3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foscarnet 0.3% cream
Study: 24853311
Drug: Adherence counseling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adherence counseling intervention based on Lifesteps, an evidence-based HIV treatment adherence intervention; median number of sessions: 10.
Study: 22330696
Drug: Docetaxel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (75 mg/m(2)) and carboplatin (AUC 6) followed by irradiation to the involved field (50.4 Gy pelvis ± 43.5 Gy paraaortic) ± brachytherapy
Study: 20645945
Drug: Remifentanil 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 1.5 ng.ml(‐1)
Study: 20645945
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (0 ng.ml(‐1) remifentanil)
Study: 20645945
Drug: Remifentanil 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 1.0 ng.ml(‐1)
Study: 17205281
Drug: Ondansetron 24
Normalized name: ondansetron 24 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 24 or 32 mg
Study: 17205281
Drug: Ondansetron higher
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron higher doses (24 or 32 mg)
Study: 16041629
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal misoprostol (200 microg every 12 hours) + Isosorbide dinitrate (5 mg single dose)
Study: 7579103
Drug: Alfentanil 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil 50 micrograms/kg, propofol at 10 mg/kg/h, reduced to 1 microgram/kg/min after 4 min.
Study: 7579103
Drug: Alfentanil 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil 75 micrograms/kg, propofol at 10 mg/kg/h, reduced to 2 micrograms/kg/min after 4 min.
Study: 2135712
Drug: Biperiden 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biperiden 2.5 mg
Study: 2135712
Drug: Atropine 1.5
Normalized name: homatropine 1.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 1.5 mg
Study: 7001207
Drug: Guanfacine (3.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanfacine (3.3 mg daily)
Study: 7001207
Drug: Clonidine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.5 mg daily)
Study: 26275705
Drug: Pharmacotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy plus cognitive‐coping therapy (pCCT)
Study: 26275705
Drug: Pharmacotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy plus psychological support (PPS)
Study: 21303262
Drug: LGNC-07 (1,680
Approvals — FDA: no, EMA: no, PMDA: no
Description: LGNC-07 (1,680 mg for 16 weeks)
Study: 21303262
Drug: LGNC-07 (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: LGNC-07 (single dose)
Study: 19843667
Drug: p16(INK4a) ELISA
Normalized name: PSEUDOPTEROGORGIA ELISABETHAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: p16(INK4a) ELISA (enhanced version, >or=6 pg/mL cut-point)
Study: 19843667
Drug: p16(INK4a) ELISA
Normalized name: PSEUDOPTEROGORGIA ELISABETHAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: p16(INK4a) ELISA (original version, >or=8 pg/mL cut-point)
Study: 14962398
Drug: Verbal prompts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verbal prompts during task preparation
Study: 11343529
Drug: Sertraline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (50 to 200 mg daily for 12 weeks)
Study: 9392394
Drug: Lispro insulin
Normalized name: Lispro insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lispro insulin injected immediately before breakfast
Study: 9392394
Drug: Regular insulin
Normalized name: Regular insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular insulin injected 20 min preprandially
Study: 7516978
Drug: Leuprolide 3.75
Normalized name: leuprolide 3.75 mg intramuscular powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide 3.75 mg depot injection every 28 days for 24 weeks
Study: 30859848
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g of vitamin C-enriched gelatin
Study: 30859848
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g of hydrolyzed collagen (HC)
Study: 26028449
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of interactive seminar and training of practice nurses
Study: 23550861
Drug: Omega-3 (1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 (1,500 mg daily for 6 months)
Study: 19253801
Drug: Sodium phosphate
Normalized name: Sodium Phosphate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium phosphate preparation
Study: 21225849
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of 0.46 mg/kg dose of cocaine
Study: 7667717
Drug: 5-day regimen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-day regimen (300 mg initial dose followed by 100 mg for another 4 days)
Study: 7667717
Drug: 7-day regimen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 7-day regimen (160 mg initial dose followed by 80 mg daily for another 6 days)
Study: 29745804
Drug: 1,000 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 µg salbutamol (SAL)
Study: 25564322
Drug: Daikenchuto (DKT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daikenchuto (DKT) 7.5 g/day, t.i.d. for 3 months
Study: 16429299
Drug: Isotretinoin 0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotretinoin 0.8 mg/kg for 4 weeks
Study: 15143418
Drug: Salbutamol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (200 micro g)
Study: 15143418
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide (36 micro g)
Study: 1615182
Drug: Amoxy 500
Normalized name: Amoxi Drop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxy 500 mg plus bromhexeine 8 mg
Study: 1615182
Drug: Plain amoxy
Normalized name: Amoxi Drop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain amoxy 500 mg
Study: 6389377
Drug: Captopril (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (50 mg) after fasting
Study: 6389377
Drug: Captopril (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (50 mg) with antacid
Study: 6389377
Drug: Captopril (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (50 mg) after a meal
Study: 28952218
Drug: Javanica oil
Normalized name: javanicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Javanica oil emulsion injection (JOEI) combined with radiotherapy (RT)
Study: 25127208
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg ponesimod
Study: 25127208
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg ponesimod
Study: 25127208
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg ponesimod (maintenance)
Study: 25127208
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg ponesimod (maintenance)
Study: 25127208
Drug: Placebo (swapped
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (swapped from 20 mg)
Study: 25127208
Drug: Placebo (swapped
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (swapped from 40 mg)
Study: 17290061
Drug: Ifosfamide 1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ifosfamide 1.6 g/m2 IV daily for 3 days plus paclitaxel 135 mg/m2 by 3‐hour infusion on day 1 (arm 2)
Study: 17290061
Drug: Ifosfamide 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ifosfamide 2.0 g/m2 IV daily for 3 days (arm 1)
Study: 15458510
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (chemo and radiotherapy)
Study: 7519979
Drug: Clonidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (150 micrograms in 10 mL of saline)
Study: 7519979
Drug: Synthetic porcine
Normalized name: Secretin synthetic porcine
DrugBank: Secretin porcine (DB09527)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synthetic porcine galanin (500 micrograms in 100 mL of saline)
Study: 3287815
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g metronidazole
Study: 3287815
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g metronidazole + 3 g nalidixic acid
Study: 3287815
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g metronidazole (3-4 hours preoperatively)
Study: 28549439
Drug: Abdominal aortic
Normalized name: chloroxylenol / hydrocortisone / pramoxine hydrochloride Otic Solution [Cortic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abdominal aortic balloon occlusion (AABO) in combination with cesarean section
Study: 23620949
Drug: 2 Hz/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 Hz/100 Hz EA treatment group (group B)
Study: 23620949
Drug: 2 Hz
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 Hz EA treatment group (group A)
Study: 23620949
Drug: 100 Hz
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 Hz EA treatment group (group C)
Study: 16939905
Drug: Tazarotene treatment
Normalized name: Tazarotene
DrugBank: Tazarotene (DB00799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tazarotene treatment
Study: 12671829
Drug: Oral calcitriol
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral calcitriol pulse therapy (twice weekly for 3 months)
Study: 12671829
Drug: Placebo (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (twice weekly for 3 months)
Study: 10630940
Drug: Fluocinolone acetonide
Normalized name: Fluocinolone Acetonide
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluocinolone acetonide in an oral base 0.1%
Study: 10630940
Drug: Fluocinolone acetonide
Normalized name: Fluocinolone Acetonide
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluocinolone acetonide gel no. 1
Study: 10630940
Drug: Fluocinolone acetonide
Normalized name: Fluocinolone Acetonide
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluocinolone acetonide gel no. 2
Study: 9175396
Drug: Dexamethasone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.5 mg/kg/dose daily for 3 days)
Study: 31935026
Drug: Counseling behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Counseling behavioral intervention promoting consumption of 7 or more daily vegetable servings (MEAL intervention; n=237)
Study: 25175875
Drug: Mass drug
Normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mass drug administration with praziquantel
Study: 22246963
Drug: Commercial drug
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercial drug alerts
Study: 19246726
Drug: PM101 (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: PM101 (150 mg)
Study: 21257800
Drug: Intravenous amiodarone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous amiodarone (150 mg)